Anti-Human NOTCH3 Recombinant Antibody (59R1) (CAT#: TAB-559MZ)

Figure 1 Anti-Notch2/3 antibody 59R1 inhibits Notch2 signaling in luciferase reporter assays.

59R11 blocks hDLL4-induced Notch2 reporter activity.

Figure 2 Anti-Notch2/3 antibody 59R1 inhibits Notch2 signaling in luciferase reporter assays.

59R1 blocks hJAG1-induced Notch2 reporter activity.

Figure 3 Anti-Notch2/3 antibody 59R1 inhibits Notch2 signaling in luciferase reporter assays.

59R1 blocks hJAG2-induced Notch2 reporter activity.

Figure 4 Notch2/3 Receptor Antibody 59R1 Inhibits Tumor Formation and Growth in vivo.

Anti-Notch2/3 (59R1) Inhibits the Formation of PE13 Breast Tumors. NOD/SCID mice injected with PE13 breast tumor cells were treated with control antibody (squares) or anti-Notch2/3 antibody 59R1 (open triangles) two days after cell injection and tumor volume (y-axis, mm³) was measured across time (x-axis, days post cell injection).

Figure 5 Notch2/3 Receptor Antibody 59R1 Inhibits Tumor Formation and Growth in vivo.

Anti-Notch2/3 (59R1) Inhibits Formation of T3 Breast Tumors. NOD/SCID mice injected with T3 breast tumor cells were treated with control antibody (squares) or anti-Notch2/3 antibody 59R1 (open triangles) two days after cell injection, and tumor volume (y-axis, mm³) was measured across time (x-axis, days post cell injection).

Figure 6 Notch2/3 Receptor Antibody 59R1 Inhibits Tumor Formation and Growth in vivo.

Anti-Notch2/3 (59R1) Inhibits the Growth of T3 Breast Tumors. NOD/SCID mice injected with T3 breast tumor cells were treated with control antibody (solid bars) or anti-Notch2/3 antibody 59R1 (open bars) after tumor volume reached a size between 65 to 200 mm³.

Figure 7 Anti-Notch2/3 antibody 59R1 decreases cancer stem cell frequency in B51 breast tumor.

Figure 1 Anti-Human NOTCH3 Recombinant Antibody (TAB-559MZ) in FC

Flow cytometry analysis of U87 MG cells with purified antibody TAB-559MZ (QCAb253, Blue). Cells were blocked with Human TruStain FcXTM and washed with 0.5% BSA-PBS. Cells were then incubated with TAB-559MZ (5 μl/5x10^5 cells) for 60 min at 4°C. The secondary antibody was FITC anti-human IgG antibody (3 μl) for 60 min at 4°C.